You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物(01477.HK)收購兩眼科藥物內地資產 涉3,500萬美元
阿思達克 08-24 08:44
歐康維視生物-B(01477.HK)公布,旗下附屬香港歐康維視與諾華訂立資產購買協議,涉及收購在內地的埃美丁及貝特舒權利的資產,總代價為3,500萬美元。轉移資產主要包括僅與該地區的該等產品相關的上市許可、知識產權(包括製造工藝)、賬簿及記錄、宣傳材料、監管資料及合約。 埃美丁為一種無菌滴眼液,適用於治療過敏性結膜炎,暫時緩解其症狀及徵候。貝特舒為一種無菌眼用懸浮液,適用於降低由慢性開角型青光眼或高眼壓症引起的眼內壓治療。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account